BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bai DS, Zhang C, Chen P, Jin SJ, Jiang GQ. The prognostic correlation of AFP level at diagnosis with pathological grade, progression, and survival of patients with hepatocellular carcinoma. Sci Rep. 2017;7:12870. [PMID: 28993684 DOI: 10.1038/s41598-017-12834-1] [Cited by in Crossref: 59] [Cited by in F6Publishing: 64] [Article Influence: 11.8] [Reference Citation Analysis]
Number Citing Articles
1 Granat LM, Kambhampati O, Klosek S, Niedzwecki B, Parsa K, Zhang D. The promises and challenges of patient-derived tumor organoids in drug development and precision oncology. Animal Model Exp Med 2019;2:150-61. [PMID: 31773090 DOI: 10.1002/ame2.12077] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
2 Yu T, Lu S, Xie W. Downregulation of GNA14 in hepatocellular carcinoma indicates an unfavorable prognosis. Oncol Lett 2020;20:165-72. [PMID: 32565944 DOI: 10.3892/ol.2020.11538] [Reference Citation Analysis]
3 Chen Y, Zhang J, Liu J, Wang J, Shi C, Lu L, Cheng X, Niu G, Zhang S, Cui D. The Expression and Clinical Significance of PCNAP1 in Hepatocellular Carcinoma Patients. Journal of Immunology Research 2022;2022:1-7. [DOI: 10.1155/2022/1817694] [Reference Citation Analysis]
4 Taha H, Elfar N, Haffez H, Hassan ZA. Raptinal silver nanoparticles: new therapeutic advances in hepatocellular carcinoma mouse model. Naunyn-Schmiedeberg's Arch Pharmacol 2021;394:279-89. [DOI: 10.1007/s00210-020-01973-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
5 Jamwal R, Krishnan V, Kushwaha DS, Khurana R. Hepatocellular carcinoma in non-cirrhotic versus cirrhotic liver: a clinico-radiological comparative analysis. Abdom Radiol (NY) 2020;45:2378-87. [PMID: 32372205 DOI: 10.1007/s00261-020-02561-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
6 Zang C, Zhao Y, Qin L, Liu G, Sun J, Li K, Zhao Y, Sheng S, Zhang H, He N, Zhao P, Wang Q, Li X, Peng Y, Dong T, Zhang Y. Distinct tumour antigen-specific T-cell immune response profiles at different hepatocellular carcinoma stages. BMC Cancer 2021;21:1007. [PMID: 34496797 DOI: 10.1186/s12885-021-08720-9] [Reference Citation Analysis]
7 Omran MM, Farid K, Omar MA, Emran TM, El-Taweel FM, Tabll AA. A combination of α-fetoprotein, midkine, thioredoxin and a metabolite for predicting hepatocellular carcinoma. Ann Hepatol 2020;19:179-85. [PMID: 31648804 DOI: 10.1016/j.aohep.2019.09.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
8 Rich NE, John BV, Parikh ND, Rowe I, Mehta N, Khatri G, Thomas SM, Anis M, Mendiratta-Lala M, Hernandez C, Odewole M, Sundaram LT, Konjeti VR, Shetty S, Shah T, Zhu H, Yopp AC, Hoshida Y, Yao FY, Marrero JA, Singal AG. Hepatocellular Carcinoma Demonstrates Heterogeneous Growth Patterns in a Multicenter Cohort of Patients With Cirrhosis. Hepatology 2020;72:1654-65. [PMID: 32017165 DOI: 10.1002/hep.31159] [Cited by in Crossref: 57] [Cited by in F6Publishing: 51] [Article Influence: 28.5] [Reference Citation Analysis]
9 Lin B, Dong X, Wang Q, Li W, Zhu M, Li M. AFP-Inhibiting Fragments for Drug Delivery: The Promise and Challenges of Targeting Therapeutics to Cancers. Front Cell Dev Biol 2021;9:635476. [PMID: 33898423 DOI: 10.3389/fcell.2021.635476] [Reference Citation Analysis]
10 Jearth V, Patil PS, Mehta S, Sundaram S, Seth V, Goel M, Patkar S, Bal M, Rao V. Correlation of Clinicopathological Profile, Prognostic Factors, and Survival Outcomes with Baseline Alfa-Fetoprotein Levels in Patients With Hepatocellular Carcinoma: A Biomarker that is Bruised but Not Broken. Journal of Clinical and Experimental Hepatology 2021. [DOI: 10.1016/j.jceh.2021.11.006] [Reference Citation Analysis]
11 Li Z, Xiao D, Li X, Zhan P, Wang J, Zhang H. Early recurrence detected in hepatocellular carcinoma patients after transcatheter arterial chemoembolization treatment with plasma cell-free DNA. Eur J Gastroenterol Hepatol 2019;31:885-92. [PMID: 30807446 DOI: 10.1097/MEG.0000000000001373] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
12 Barreto SG, Strasser SI, Mccaughan GW, Fink MA, Jones R, Mccall J, Munn S, Macdonald GA, Hodgkinson P, Jeffrey GP, Jaques B, Crawford M, Brooke-smith ME, Chen JW. Expansion of Liver Transplantation Criteria for Hepatocellular Carcinoma from Milan to UCSF in Australia and New Zealand and Justification for Metroticket 2.0. Cancers 2022;14:2777. [DOI: 10.3390/cancers14112777] [Reference Citation Analysis]
13 Xu Y, Guo Q, Wei L. The Emerging Influences of Alpha-Fetoprotein in the Tumorigenesis and Progression of Hepatocellular Carcinoma. Cancers (Basel) 2021;13:5096. [PMID: 34680245 DOI: 10.3390/cancers13205096] [Reference Citation Analysis]
14 Singh G, Yoshida EM, Rathi S, Marquez V, Kim P, Erb SR, Salh BS. Biomarkers for hepatocellular cancer. World J Hepatol 2020; 12(9): 558-573 [PMID: 33033565 DOI: 10.4254/wjh.v12.i9.558] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
15 Zhou Y, Liu L, Liu Y, Zhou P, Yan Q, Yu H, Chen X, Zhu F. Implication of human endogenous retrovirus W family envelope in hepatocellular carcinoma promotes MEK/ERK-mediated metastatic invasiveness and doxorubicin resistance. Cell Death Discov 2021;7:177. [PMID: 34238921 DOI: 10.1038/s41420-021-00562-5] [Reference Citation Analysis]
16 Er E, Sánchez-Iglesias A, Silvestri A, Arnaiz B, Liz-Marzán LM, Prato M, Criado A. Metal Nanoparticles/MoS2 Surface-Enhanced Raman Scattering-Based Sandwich Immunoassay for α-Fetoprotein Detection. ACS Appl Mater Interfaces 2021;13:8823-31. [PMID: 33583183 DOI: 10.1021/acsami.0c22203] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Munson PV, Adamik J, Butterfield LH. Immunomodulatory impact of α-fetoprotein. Trends Immunol 2022:S1471-4906(22)00075-8. [PMID: 35550875 DOI: 10.1016/j.it.2022.04.001] [Reference Citation Analysis]
18 Liu Z, Pu Y, Bao Y, He S. Investigation of Potential Molecular Biomarkers for Diagnosis and Prognosis of AFP-Negative HCC. Int J Gen Med 2021;14:4369-80. [PMID: 34408477 DOI: 10.2147/IJGM.S323868] [Reference Citation Analysis]
19 Zheng Y, Zhu M, Li M. Effects of alpha-fetoprotein on the occurrence and progression of hepatocellular carcinoma. J Cancer Res Clin Oncol 2020;146:2439-46. [DOI: 10.1007/s00432-020-03331-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
20 Bai H, Pan Y, Qi L, Liu L, Zhao X, Dong H, Cheng X, Qin W, Wang X. Development a hydrazide-functionalized thermosensitive polymer based homogeneous system for highly efficient N-glycoprotein/glycopeptide enrichment from human plasma exosome. Talanta 2018;186:513-20. [PMID: 29784395 DOI: 10.1016/j.talanta.2018.04.098] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
21 He N, Feng G, Zhang C, Wu F, Zhang T, Yang Y. Plasma levels of methylated septin 9 are capable of detecting hepatocellular carcinoma and hepatic cirrhosis. Mol Med Rep 2020;22:2705-14. [PMID: 32945374 DOI: 10.3892/mmr.2020.11356] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Mähringer-Kunz A, Weinmann A, Schmidtmann I, Koch S, Schotten S, Pinto Dos Santos D, Pitton MB, Dueber C, Galle PR, Kloeckner R. Validation of the SNACOR clinical scoring system after transarterial chemoembolisation in patients with hepatocellular carcinoma. BMC Cancer 2018;18:489. [PMID: 29703174 DOI: 10.1186/s12885-018-4407-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
23 Zhou D, Liu X, Wang X, Yan F, Wang P, Yan H, Jiang Y, Yang Z. A prognostic nomogram based on LASSO Cox regression in patients with alpha-fetoprotein-negative hepatocellular carcinoma following non-surgical therapy. BMC Cancer 2021;21:246. [PMID: 33685417 DOI: 10.1186/s12885-021-07916-3] [Reference Citation Analysis]
24 Jensen C, Holm Nielsen S, Eslam M, Genovese F, Nielsen MJ, Vongsuvanh R, Uchila R, van der Poorten D, George J, Karsdal MA, Leeming DJ, Willumsen N. Cross-Linked Multimeric Pro-Peptides of Type III Collagen (PC3X) in Hepatocellular Carcinoma - A Biomarker That Provides Additional Prognostic Value in AFP Positive Patients. J Hepatocell Carcinoma 2020;7:301-13. [PMID: 33204663 DOI: 10.2147/JHC.S275008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
25 Bhutiani N, O'brien SJ, Priddy EE, Egger ME, Hong YK, Mercer MK, Mcmasters KM, Martin RC, Potts MH, Scoggins CR. Correlating serum alpha-fetoprotein in hepatocellular carcinoma with response to Yttrium-90 transarterial radioembolization with glass microspheres (TheraSphere™). HPB 2020;22:1330-8. [DOI: 10.1016/j.hpb.2019.12.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
26 Xing H, Qiu H, Ding X, Han J, Li Z, Wu H, Yan C, Li H, Han R, Zhang H, Li C, Wang M, Wu M, Shen F, Zheng Y, Yang T. Clinical performance of α-L-fucosidase for early detection of hepatocellular carcinoma. Biomark Med 2019;13:545-55. [PMID: 31140827 DOI: 10.2217/bmm-2018-0414] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
27 Mouchli M, Reddy S, Gerrard M, Boardman L, Rubio M. Usefulness of neutrophil-to-lymphocyte ratio (NLR) as a prognostic predictor after treatment of hepatocellular carcinoma." Review article. Ann Hepatol 2021;22:100249. [PMID: 32896610 DOI: 10.1016/j.aohep.2020.08.067] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
28 Zhou K, Mehta N. Downstaging to Liver Transplant: Success Involves Choosing the Right Patient. Clin Liver Dis 2020;24:665-79. [PMID: 33012452 DOI: 10.1016/j.cld.2020.07.005] [Reference Citation Analysis]
29 Muscari F, Maulat C. Preoperative alpha-fetoprotein (AFP) in hepatocellular carcinoma (HCC): is this 50-year biomarker still up-to-date? Transl Gastroenterol Hepatol 2020;5:46. [PMID: 33073041 DOI: 10.21037/tgh.2019.12.09] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
30 Motawi TMK, Sabry D, Shehata NI, William MM, Fahim AT. Impact of FOXP1 rs2687201 genetic variant on the susceptibility to HCV-related hepatocellular carcinoma in Egyptians. J Biochem Mol Toxicol 2021;:e22965. [PMID: 34783112 DOI: 10.1002/jbt.22965] [Reference Citation Analysis]
31 Luo L, Cai L, Luo L, Tang Z, Meng X. Silencing activating transcription factor 2 promotes the anticancer activity of sorafenib in hepatocellular carcinoma cells. Mol Med Rep 2018;17:8053-60. [PMID: 29693700 DOI: 10.3892/mmr.2018.8921] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
32 Xia R, Peng J, He J, Jiang P, Yuan C, Liu X, Yao Y. The Serious Challenge of Occult Hepatitis B Virus Infection-Related Hepatocellular Carcinoma in China. Front Microbiol 2022;13:840825. [DOI: 10.3389/fmicb.2022.840825] [Reference Citation Analysis]
33 Kelley RK, Meyer T, Rimassa L, Merle P, Park JW, Yau T, Chan SL, Blanc JF, Tam VC, Tran A, Dadduzio V, Markby DW, Kaldate R, Cheng AL, El-Khoueiry AB, Abou-Alfa GK. Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma. Clin Cancer Res 2020;26:4795-804. [PMID: 32636319 DOI: 10.1158/1078-0432.CCR-19-3884] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
34 Rondon A, Mahri S, Morales‐yanez F, Dumoulin M, Vanbever R. Protein Engineering Strategies for Improved Pharmacokinetics. Adv Funct Mater 2021;31:2101633. [DOI: 10.1002/adfm.202101633] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
35 Isaac A, Mohamed SM, Ahmed OA, Hassan AGM, Rasmy HS. Amphiregulin as a novel diagnostic and prognostic biomarker of hepatocellular carcinoma before and after locoregional treatment. Egypt J Intern Med 2021;33. [DOI: 10.1186/s43162-021-00078-5] [Reference Citation Analysis]
36 Su B, Bei Z, Pei H, Xie X, Sun Z, Chen Q, Cao H, Liu X. Generation of a nanobody-alkaline phosphatase heptamer fusion for ratiometric fluorescence immunodetection of trace alpha fetoprotein in serum. Int J Biol Macromol 2022;201:507-15. [PMID: 35063488 DOI: 10.1016/j.ijbiomac.2022.01.056] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Saad H, Zahran MA, Hendy O, Abdel-Samiee M, Bedair HM, Abdelsameea E. Matrix Metalloproteinase-11 Gene Polymorphisms as a Risk for Hepatocellular Carcinoma Development in Egyptian Patients. Asian Pac J Cancer Prev 2020;21:3725-34. [PMID: 33369474 DOI: 10.31557/APJCP.2020.21.12.3725] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
38 Smart SK, Vasileiadi E, Wang X, DeRyckere D, Graham DK. The Emerging Role of TYRO3 as a Therapeutic Target in Cancer. Cancers (Basel) 2018;10:E474. [PMID: 30501104 DOI: 10.3390/cancers10120474] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 7.0] [Reference Citation Analysis]
39 Bednarsch J, Czigany Z, Heise D, Joechle K, Luedde T, Heij L, Bruners P, Ulmer TF, Neumann UP, Lang SA. Prognostic evaluation of HCC patients undergoing surgical resection: an analysis of 8 different staging systems. Langenbecks Arch Surg. 2021;406:75-86. [PMID: 33294952 DOI: 10.1007/s00423-020-02052-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
40 Lin B, Wang Q, Liu K, Dong X, Zhu M, Li M. Alpha-Fetoprotein Binding Mucin and Scavenger Receptors: An Available Bio-Target for Treating Cancer. Front Oncol 2021;11:625936. [PMID: 33718192 DOI: 10.3389/fonc.2021.625936] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Decaens T, Barone C, Assenat E, Wermke M, Fasolo A, Merle P, Blanc JF, Grando V, Iacobellis A, Villa E, Trojan J, Straub J, Bruns R, Berghoff K, Scheele J, Raymond E, Faivre S. Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression. Br J Cancer 2021;125:190-9. [PMID: 33824476 DOI: 10.1038/s41416-021-01334-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
42 Glantzounis GK, Karampa A, Peristeri DV, Pappas-Gogos G, Tepelenis K, Tzimas P, Cyrochristos DJ. Recent advances in the surgical management of hepatocellular carcinoma. Ann Gastroenterol 2021;34:453-65. [PMID: 34276183 DOI: 10.20524/aog.2021.0632] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Yu J, Xia X, Dong Y, Gong Z, Li G, Chen GG, Lai PBS. CYP1A2 suppresses hepatocellular carcinoma through antagonizing HGF/MET signaling. Theranostics 2021;11:2123-36. [PMID: 33500715 DOI: 10.7150/thno.49368] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
44 Tian H, Cao S, Hu M, Wang Y, Fu Q, Pan Y, Qin T. Identification of predictive factors in hepatocellular carcinoma outcome: A longitudinal study. Oncol Lett 2020;20:765-73. [PMID: 32566003 DOI: 10.3892/ol.2020.11581] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
45 Asimakopoulou A, Vucur M, Luedde T, Schneiders S, Kalampoka S, Weiss TS, Weiskirchen R. Perilipin 5 and Lipocalin 2 Expression in Hepatocellular Carcinoma. Cancers (Basel) 2019;11:E385. [PMID: 30893876 DOI: 10.3390/cancers11030385] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
46 Wang S, Ma H, Li X, Mo X, Zhang H, Yang L, Deng Y, Yan Y, Yang G, Liu X, Sun H. DNASE1L3 as an indicator of favorable survival in hepatocellular carcinoma patients following resection. Aging (Albany NY) 2020;12:1171-85. [PMID: 31977318 DOI: 10.18632/aging.102675] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
47 Ismail IT, Fiehn O, Elfert A, Helal M, Salama I, El-Said H. Sugar Alcohols Have a Key Role in Pathogenesis of Chronic Liver Disease and Hepatocellular Carcinoma in Whole Blood and Liver Tissues. Cancers (Basel) 2020;12:E484. [PMID: 32092943 DOI: 10.3390/cancers12020484] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
48 Fahy BN. Prognostication in oncology. J Surg Oncol 2019;120:10-6. [PMID: 30883779 DOI: 10.1002/jso.25428] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
49 Cheng Y, Luo L, Zhang J, Zhou M, Tang Y, He G, Lu Y, Wang Z, Pan M. Diagnostic Value of Different Phenotype Circulating Tumor Cells in Hepatocellular Carcinoma. J Gastrointest Surg 2019;23:2354-61. [PMID: 30805878 DOI: 10.1007/s11605-018-04067-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
50 Ahn KS, O'Brien DR, Kim YH, Kim TS, Yamada H, Park JW, Park SJ, Kim SH, Zhang C, Li H, Kang KJ, Roberts LR. Associations of Serum Tumor Biomarkers with Integrated Genomic and Clinical Characteristics of Hepatocellular Carcinoma. Liver Cancer 2021;10:593-605. [PMID: 34950182 DOI: 10.1159/000516957] [Reference Citation Analysis]
51 Ciurea AM, Gheonea DI, Schenker M, Mehedințeanu AM, Târtea GC, Vere CC. The Prognostic Correlation of Heart Rate Variability at Diagnosis with Survival of Patients with Hepatocellular Carcinoma. Diagnostics (Basel) 2021;11:890. [PMID: 34067711 DOI: 10.3390/diagnostics11050890] [Reference Citation Analysis]
52 Trojan J, Mollon P, Daniele B, Marteau F, Martín L, Li Y, Xu Q, Piscaglia F, Zaucha R, Sarker D, Lim HY, Venerito M. Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein ≥ 400 ng/mL: A Matching-Adjusted Indirect Comparison. Adv Ther 2021;38:2472-90. [PMID: 33822328 DOI: 10.1007/s12325-021-01700-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
53 Abdelhamid AM, Saber S, Youssef ME, Gaafar AGA, Eissa H, Abd-Eldayem MA, Alqarni M, Batiha GE, Obaidullah AJ, Shahien MA, El-Ahwany E, Amin NA, Etman MA, Kaddah MMY, Abd El-Fattah EE. Empagliflozin adjunct with metformin for the inhibition of hepatocellular carcinoma progression: Emerging approach for new application. Biomed Pharmacother 2022;145:112455. [PMID: 34844106 DOI: 10.1016/j.biopha.2021.112455] [Reference Citation Analysis]
54 Bedon L, Dal Bo M, Mossenta M, Busato D, Toffoli G, Polano M. A Novel Epigenetic Machine Learning Model to Define Risk of Progression for Hepatocellular Carcinoma Patients. Int J Mol Sci 2021;22:1075. [PMID: 33499054 DOI: 10.3390/ijms22031075] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
55 Wang XH, Long LH, Cui Y, Jia AY, Zhu XG, Wang HZ, Wang Z, Zhan CM, Wang ZH, Wang WH. MRI-based radiomics model for preoperative prediction of 5-year survival in patients with hepatocellular carcinoma. Br J Cancer 2020;122:978-85. [PMID: 31937925 DOI: 10.1038/s41416-019-0706-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
56 Malov SI, Malov IV, Kuvshinov AG, Marche PN, Decaens T, Macek-Jilkova Z, Yushchuk ND. Search for Effective Serum Tumor Markers for Early Diagnosis of Hepatocellular Carcinoma Associated with Hepatitis C. Sovrem Tekhnologii Med 2021;13:27-33. [PMID: 34513063 DOI: 10.17691/stm2021.13.1.03] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Caviglia GP, Ciruolo M, Olivero A, Carucci P, Rolle E, Rosso C, Abate ML, Risso A, Ribaldone DG, Tandoi F, Saracco GM, Bugianesi E, Gaia S. Prognostic Role of Serum Cytokeratin-19 Fragment (CYFRA 21-1) in Patients with Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E2776. [PMID: 32998218 DOI: 10.3390/cancers12102776] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
58 Candia J, Bayarsaikhan E, Tandon M, Budhu A, Forgues M, Tovuu LO, Tudev U, Lack J, Chao A, Chinburen J, Wang XW. The genomic landscape of Mongolian hepatocellular carcinoma. Nat Commun 2020;11:4383. [PMID: 32873799 DOI: 10.1038/s41467-020-18186-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
59 Dong JJ, Ying L, Shi KQ. Expression of the Wnt ligands gene family and its relationship to prognosis in hepatocellular carcinoma. Cancer Cell Int 2019;19:34. [PMID: 30814912 DOI: 10.1186/s12935-019-0743-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
60 Sprang M, Paret C, Faber J. CpG-Islands as Markers for Liquid Biopsies of Cancer Patients. Cells 2020;9:E1820. [PMID: 32752173 DOI: 10.3390/cells9081820] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
61 Lin H, Huang ZP, Liu J, Qiu Y, Tao YP, Wang MC, Yao H, Hou KZ, Gu FM, Xu XF. MiR-494-3p promotes PI3K/AKT pathway hyperactivation and human hepatocellular carcinoma progression by targeting PTEN. Sci Rep 2018;8:10461. [PMID: 29992971 DOI: 10.1038/s41598-018-28519-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 5.5] [Reference Citation Analysis]
62 Jinesh GG, Napoli M, Smallin MT, Davis A, Ackerman HD, Raulji P, Montey N, Flores ER, Brohl AS. Mutant p53s and chromosome 19 microRNA cluster overexpression regulate cancer testis antigen expression and cellular transformation in hepatocellular carcinoma. Sci Rep 2021;11:12673. [PMID: 34135394 DOI: 10.1038/s41598-021-91924-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Kim S, Choi Y, Kwak DW, Lee HS, Hur WJ, Baek YH, Lee SW. Prognostic factors in hepatocellular carcinoma patients with bone metastases. Radiat Oncol J 2019;37:207-14. [PMID: 31591869 DOI: 10.3857/roj.2019.00136] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
64 Chen S, Li K, Jiang J, Wang X, Chai Y, Zhang C, Deng Q, Shuai L, Feng K, Ma K, Zhang L. Low expression of organic anion-transporting polypeptide 1B3 predicts a poor prognosis in hepatocellular carcinoma. World J Surg Oncol 2020;18:127. [PMID: 32534581 DOI: 10.1186/s12957-020-01891-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
65 Zhou S, Wang Z, Li M, Wu L. Elevated Preoperative Serum CA125 Predicts Larger Tumor Diameter in Patients with Hepatocellular Carcinoma and Low AFP Levels. Biomed Res Int 2019;2019:6959637. [PMID: 31662990 DOI: 10.1155/2019/6959637] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
66 Filis P, Walker N, Robertson L, Eaton-Turner E, Ramona L, Bellingham M, Amezaga MR, Zhang Z, Mandon-Pepin B, Evans NP, Sharpe RM, Cotinot C, Rees WD, O'Shaughnessy P, Fowler PA. Long-term exposure to chemicals in sewage sludge fertilizer alters liver lipid content in females and cancer marker expression in males. Environ Int 2019;124:98-108. [PMID: 30641261 DOI: 10.1016/j.envint.2019.01.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
67 Wu M, Tan H, Gao F, Hai J, Ning P, Chen J, Zhu S, Wang M, Dou S, Shi D. Predicting the grade of hepatocellular carcinoma based on non-contrast-enhanced MRI radiomics signature. Eur Radiol. 2019;29:2802-2811. [PMID: 30406313 DOI: 10.1007/s00330-018-5787-2] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 11.3] [Reference Citation Analysis]
68 Zhou K, Zhou Q, Cai C. A genomic-clinicopathologic nomogram for predicting overall survival of hepatocellular carcinoma. BMC Cancer 2020;20:1176. [PMID: 33261584 DOI: 10.1186/s12885-020-07688-2] [Reference Citation Analysis]
69 Macek-Jilkova Z, Malov SI, Kurma K, Charrat C, Decaens T, Peretolchina NP, Marche PN, Malov IV, Yushchuk ND. Clinical and Experimental Evaluation of Diagnostic Significance of Alpha-Fetoprotein and Osteopontin at the Early Stage of Hepatocellular Cancer. Bull Exp Biol Med 2021;170:340-4. [PMID: 33452981 DOI: 10.1007/s10517-021-05063-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
70 Wang T, Zhang KH. New Blood Biomarkers for the Diagnosis of AFP-Negative Hepatocellular Carcinoma. Front Oncol 2020;10:1316. [PMID: 32923383 DOI: 10.3389/fonc.2020.01316] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
71 Wichelmann TA, Patel K, Malas A, James E. A Unique Case of Alpha-Fetoprotein-Negative Hepatoid Adenocarcinoma of the Stomach With Associated Signet Ring Cell Histological Features and Linitis Plastica. Cureus 2020;12:e11908. [PMID: 33415058 DOI: 10.7759/cureus.11908] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
72 Han Y, Cao G, Sun B, Wang J, Yan D, Xu H, Shi Q, Liu Z, Zhi W, Xu L, Liu B, Zou Y. Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study. BMC Gastroenterol 2021;21:393. [PMID: 34670512 DOI: 10.1186/s12876-021-01967-3] [Reference Citation Analysis]
73 Khazamipour N, Al-Nakouzi N, Oo HZ, Ørum-Madsen M, Steino A, Sorensen PH, Daugaard M. Oncofetal Chondroitin Sulfate: A Putative Therapeutic Target in Adult and Pediatric Solid Tumors. Cells 2020;9:E818. [PMID: 32231047 DOI: 10.3390/cells9040818] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
74 Li W, Han L, Xiao B, Li X, Ye Z. A Predictive Nomogram of Early Recurrence for Patients with AFP-Negative Hepatocellular Carcinoma Underwent Curative Resection. Diagnostics 2022;12:1073. [DOI: 10.3390/diagnostics12051073] [Reference Citation Analysis]
75 Zhong XZ, Deng Y, Chen G, Yang H. Investigation of the clinical significance and molecular mechanism of miR-21-5p in hepatocellular carcinoma: A systematic review based on 24 studies and bioinformatics investigation. Oncol Lett 2019;17:230-46. [PMID: 30655760 DOI: 10.3892/ol.2018.9627] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
76 Liu H, Chen H, Wu X, Sun Y, Wang Y, Zeng Y, Chen G, Liu X, Xing X, Zhao B, Liu J. The serum proteomics tracking of hepatocellular carcinoma early recurrence following radical resection. Cancer Manag Res 2019;11:2935-46. [PMID: 31114342 DOI: 10.2147/CMAR.S190561] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
77 Tsai MC, Yen YH, Chang KC, Hung CH, Chen CH, Lin MT, Hu TH. Elevated levels of serum urokinase plasminogen activator predict poor prognosis in hepatocellular carcinoma after resection. BMC Cancer 2019;19:1169. [PMID: 31791275 DOI: 10.1186/s12885-019-6397-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
78 Gosain R, Anwar S, Miller A, Iyer R, Mukherjee S. Interleukin-6 as a biomarker in patients with hepatobiliary cancers. J Gastrointest Oncol 2019;10:537-45. [PMID: 31183205 DOI: 10.21037/jgo.2019.01.09] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
79 Moeckli B, Majno P, Orci LA, Peloso A, Toso C. Liver Transplantation Selection and Allocation Criteria for Hepatocellular Carcinoma: A European Perspective. Semin Liver Dis 2021;41:172-81. [PMID: 33957694 DOI: 10.1055/s-0041-1723032] [Reference Citation Analysis]
80 Zhao T, Jia L, Li J, Ma C, Wu J, Shen J, Dang L, Zhu B, Li P, Zhi Y, Lan R, Xu Y, Hao Z, Chai Y, Li Q, Hu L, Sun S. Heterogeneities of Site-Specific N-Glycosylation in HCC Tumors With Low and High AFP Concentrations. Front Oncol 2020;10:496. [PMID: 32426269 DOI: 10.3389/fonc.2020.00496] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]